Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
+$1.50 today
- Market cap
- $10.34B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
Volume 0.68M
Average 0.58M
KYMR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Kymera Therapeutics, Inc.NASDAQ: KYMR
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $21.13M rose 19.7% year over year, ahead of the +15.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.
Context
- Selling, general & admin amounted to 174.0% of revenue in FY2025, up 39.0 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 17 analysts of $103.85M (+52.3%) for the fiscal year ending Dec 2026, a step up from the +7.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $21.13M+3.8% QoQ
- Last fiscal yearDec 2025
- $68.2M+7.3% YoY
- LTMJun 2026
- $75.77M+15.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 68.2M USD
- Year-over-year change
- +7.3%
- 4-year CAGR
- +17.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 68.2M | +7.3% |
| FY2024 | 2024-12-31 | 63.53M | +15.4% |
| FY2023 | 2023-12-31 | 55.04M | +25.6% |
| FY2022 | 2022-12-31 | 43.83M | +20.6% |
| FY2021 | 2021-12-31 | 36.35M | — |
Selling, General & Admin vs competitors
How KYMR compares with its peers on the latest reported figures
- KYMR's LTM Jun 2026 selling, general & admin of $75.77M is the 3rd highest of the 5 companies compared; the peer median is $58.03M.
- Its year-over-year change of +15.3% is the 2nd highest of 5, against a peer median of -4.0%.
- Selling, general & admin amounts to 72.2% of revenue for KYMR, versus a peer median of 92.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $86.5M | -47.9% | +3.9% | 96.8% | |
| LTM Aug 2026 | $78.21M | +57.0% | +11.6% | 11.1% | |
| LTM Jun 2026 | $75.77M | +15.3% | +15.9% | 72.2% | |
| LTM Mar 2026 | $37.85M | +8.5% | +10.0% | 88.1% | |
| LTM Mar 2026 | $34.4M | -16.4% | -5.4% | 98.7% | |
| Peer median (excluding KYMR) | $58.03M | -4.0% | +7.0% | 92.4% | |
Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 137.02M | 164.25M | 189.08M | 240.25M | 316.6M |
| Selling, General & Admin | 36.35M | 43.83M | 55.04M | 63.53M | 68.2M |
| Operating Expenses | 173.36M | 208.08M | 244.12M | 308.71M | 388.6M |
| Depreciation & Amortization | 2.4M | 2.98M | 3.57M | 7.37M | 8.31M |
| EBITDA | (97.65M) | (151.66M) | (143.2M) | (216.24M) | (303.06M) |
| EBITDA Margin | -134.1% | -323.9% | -182.2% | -459.4% | -773.1% |
| Operating Income | (100.53M) | (161.26M) | (165.53M) | (261.64M) | (349.4M) |
| Operating Margin | -138.0% | -344.4% | -210.6% | -555.8% | -891.3% |
| Interest Income | 488K | 6.62M | 18.76M | 38.03M | 38.03M |
| Interest Expense | 175K | 176K | 196K | 249K | 249K |
| Other Income / Expenses | 313K | 6.45M | 18.57M | 37.78M | 37.78M |
| Income Before Tax | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.62M) |
| Pre-Tax Margin | -137.6% | -330.6% | -187.0% | -475.6% | -795.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.4M) |
| Net Margin | -137.6% | -330.6% | -187.0% | -475.6% | -794.4% |
| EPS (Basic) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| EPS (Diluted) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| Weighted Avg Shares | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M |
| Weighted Avg Shares (Diluted) | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M |
Kymera Therapeutics, Inc.
NASDAQ:KYMR
Intrinsic Alpha fair value
Locked
Current Price
$121.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.